Insulet, the developer of a discreet and easy-to-use insulin infusion system for diabetics, announced the terms of its IPO Wednesday. The company plans to offer 6.7 million shares at $14.00 to $16.00 per share. JPMorgan and Merrill Lynch are bookrunning the deal.
